王晓川 1韩水仲 2赵文庆 3孙良起 1蒋欢欢 1郑国宝1
作者信息
- 1. 中国人民解放军第150中心医院，河南洛阳471031
- 2. 普莱柯生物工程股份有限公司，河南洛阳471031
- 3. 洛阳市第一中医院，河南洛阳471031
- 折叠
摘要
Abstract
Objective To evaluate the clinical value of multi-tumor markers protein biochip in the diagnosis of lung cancer. Methods Serum CA125, CA19-9, Ferritin, CA15-3, CA242, CEA, AFP, NSE, PSA, f-PSA, HGH,β-HCG were detected by multi-tumor markers protein biochip in 157 patients with lung cancer, 177 patients with benign lung disease, and 41 healthy people in control group. Results The positive rate of 12 tumor markers ( 92 . 36%) in lung cancer was significant higher than that in benign lung disease (76. 83%) and healthy people (7. 32%)(all P<0. 01). The positive rate of CEA and CA242 in lung cancer showed significant differences compared with benign lung disease and healthy people ( all P<0. 05), but no significant differences inβ-HCG, AFP, f-PSA, PSA, HGH. Serum levels of CA19-9, NSE, CEA, CA242, CA125, CA153 were significant higher in lung cancer than that in benign lung disease and healthy people (all P <0.05), but no significant differences in β-HCG, f-PSA, PSA, HGH (all P >0. 05). Conclusion Multi-tumor markers biochip might contribute to the early diagnosis for lung cancer, but not to be a definite diagnosis biomarker.关键词
肺癌/肿瘤标志物/多肿瘤标志物蛋白芯片Key words
lung cancer/tumor markers/multi-tumor markers protein biochip分类
医药卫生
